BVXV BiondVax Pharmaceuticals Ltd.

19.9
-0.67  -3%
Previous Close 20.57
Open 20.42
Price To Book -34.31
Market Cap 200,169,941
Shares 10,058,791
Volume 65,148
Short Ratio
Av. Daily Volume 78,635
Stock charts supplied by TradingView

NewsSee all news

  1. BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants

    JERUSALEM, May 20, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the M‑001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately $4.2 million since

  2. BiondVax Announces Upcoming Expiration of Public Warrants

    JERUSALEM, May 4, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the universal influenza vaccine candidate M-001, today published a reminder that its publicly traded warrants (traded on

  3. New Directors Elected to BiondVax's Board of Directors

    JERUSALEM, March 24, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the

  4. BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial

    JERUSALEM, March 19, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) today issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal, clinical efficacy, Phase 3 trial in

  5. Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials

    JERUSALEM, Feb. 5, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced today that preliminary data from the Phase 2 clinical trial of BiondVax's M-001 universal influenza vaccine candidate have

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due by the end of 2020.
M-001
Universal flu vaccine
Phase 2 data due 2Q 2020.
M-001
Universal flu vaccine

Latest News

  1. BiondVax Announces Receipt of $4.2 Million Through Exercise of Warrants

    JERUSALEM, May 20, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the M‑001 universal influenza vaccine candidate, today announced receipt of proceeds of approximately $4.2 million since

  2. BiondVax Announces Upcoming Expiration of Public Warrants

    JERUSALEM, May 4, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the universal influenza vaccine candidate M-001, today published a reminder that its publicly traded warrants (traded on

  3. New Directors Elected to BiondVax's Board of Directors

    JERUSALEM, March 24, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), developer of the universal influenza vaccine candidate M-001, announced that all proposed resolutions were approved at the

  4. BiondVax's CEO Comments on Impact of COVID-19 Pandemic on the Company's Ongoing Phase 3 Clinical Trial

    JERUSALEM, March 19, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) today issued an update regarding the impact of the COVID-19 pandemic on the ongoing pivotal, clinical efficacy, Phase 3 trial in

  5. Preliminary Data from NIH/NIAID-sponsored Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Validates Results of Previous Clinical Trials

    JERUSALEM, Feb. 5, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced today that preliminary data from the Phase 2 clinical trial of BiondVax's M-001 universal influenza vaccine candidate have

  6. BiondVax Announces Warrant Agreement Amendment to Permit Holders of Warrants to Exercise Both on a Cash and Cashless Basis

    JERUSALEM, Jan. 16, 2020 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate,

  7. BiondVax Announces Third Quarter 2019 Financial Results and Business Update

    JERUSALEM, Nov. 26, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate,

  8. Enrollment and Randomization of 12,463 Participants Complete in BiondVax's Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine trial

    JERUSALEM, Nov. 18, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) announced today that enrollment and randomization of 12,463 participants in the pivotal, clinical efficacy, Phase 3 trial of the M-001

  9. BiondVax Receives €4M From the European Investment Bank (EIB) in Support of Ongoing Universal Influenza Vaccine Pivotal Phase 3 Trial

    JERUSALEM, Oct. 7, 2019 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV), a phase 3 clinical stage biopharmaceutical company focused on developing and commercializing the M-001 clinical Phase 3 Universal